Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02602327
Other study ID # 16452
Secondary ID NCI-2017-01321
Status Completed
Phase Phase 1
First received
Last updated
Start date January 9, 2017
Est. completion date August 31, 2021

Study information

Verified date July 2022
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I dose escalation study (3+3 design) with a dose expansion arm (12 patients) designed to evaluate safety of the combination of Tas-102 and radioembolization using Yttrium-90 (90Y) resin microspheres for patients with chemotherapy-refractory liver-dominant chemotherapy-refractory metastatic colorectal cancer (mCRC).


Description:

Randomized studies have demonstrated that Tas-102 has single agent activity against chemotherapy refractory colorectal cancer. A recent pre-clinical study has shown that Tas-102 may have activity as a radiation sensitizer in bladder cancer cell lines. Benefit of single agent Tas-102 against chemotherapy refractory colon cancer and the drug's promise a radiosensitizer make Tas-102 a potential candidate drug for testing in combination with radioembolization using Yttrium-90 resin microspheres in patients with liver-dominant chemotherapy-refractory mCRC. This is a phase I dose escalation study with a dose expansion arm designed to evaluate safety of the combination of Tas-102 and radioembolization using 90Y resin microspheres for patients with chemotherapy-refractory colon or rectal adenocarcinoma metastatic to the liver.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date August 31, 2021
Est. primary completion date May 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female, 18 years of age or older, and of any ethnic or racial group. 2. Diagnosis of unresectable metastatic colorectal adenocarcinoma with liver-dominant bilobar disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria. 3. Disease progression or intolerance to at least two prior Food and Drug Administration-approved therapeutic regimens. 4. If extrahepatic disease is present, it must be asymptomatic. 5. If a primary tumor is in place, it must be asymptomatic. 6. Measurable target tumors using standard imaging techniques (RECIST v. 1.1 criteria). 7. Tumor replacement < 50% of total liver volume. 8. Current Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 through screening to first treatment on study. 9. Completion of prior systemic therapy at least 14 days prior to enrollment. 10. Able to understand informed consent. Exclusion Criteria: 1. At risk of hepatic or renal failure - Serum creatinine > 1.5 mg/dl - Serum bilirubin > 1.3 mg/ml - Albumin < 2.0 g/dL - Aspartate and/or alanine aminotransferase level > 5 times upper normal limit - Any history of hepatic encephalopathy - Cirrhosis or portal hypertension - Clinically evident ascites (trace ascites on imaging is acceptable) 2. Contraindications to angiography and selective visceral catheterization - Any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device) - Severe allergy or intolerance to contrast agents, narcotics, or sedatives that cannot be managed medically 3. Symptomatic lung disease 4. Prior therapy with Tas-102. 5. Contraindications to Tas-102 - Absolute neutrophil count < 1,500/µl - Platelet count < 75,000/µl - Allergy or intolerance to Tas-102 6. Unresolved toxicity of greater than or equal to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 due to prior therapies. 7. Evidence of potential delivery of - Greater than 30 Gy absorbed dose of radiation to the lungs during a single 90Y resin microsphere administration; or - Cumulative delivery of radiation to the lungs > 50 Gy over multiple treatments. 8. Evidence of any detectable Tc-99m macro aggregated albumin flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow. 9. Previous radiation therapy to the lungs and/or to the upper abdomen 10. Any prior arterial liver-directed therapy, including chemoembolization, bland embolization, and 90Y radioembolization 11. Any intervention for, or compromise of the ampulla of Vater 12. Active uncontrolled infection. Presence of latent or medication-controlled HIV and/or viral hepatitis is allowed. 13. Significant extrahepatic disease - Symptomatic extrahepatic disease (including primary tumor, if unresected). - Greater than 10 pulmonary nodules (each < 20 mm in diameter) or combined diameter of all pulmonary nodules > 15 cm. - Peritoneal carcinomatosis 14. Life expectancy less than 3 months 15. Pregnant or lactating female 16. In the investigator's judgment, any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of radioembolization or Tas-102.

Study Design


Intervention

Drug:
Tas-102
Oral nucleoside antitumor agent consisting of a,a,a-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
Device:
SIR-Sphere
20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope

Locations

Country Name City State
United States University of California San Francisco San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
University of California, San Francisco Sirtex Medical, Taiho Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine dose limiting toxicities (DLT) Any adverse events grade = 3 will be reviewed by the treating interventional radiologist and medical oncologist within 24 hours of being informed event. If none of the 3 patients in a cohort experiences a DLT, another 3 patients will be treated at the next higher dose level. However, if 1 of the first 3 patients experiences a DLT, 3 more patients will be treated at the same dose level. The dose escalation will continue until at least 2 patients among a cohort of 3-6 patients experience DLTs (i.e., = 33% of patients with a dose-limiting toxicity at that dose level) or until 3-6 patients had been treated at TAS-102 dose of 35mg/m2 per day in 2 divided doses (up to a maximum of 80 mg per dose) administered concurrently with radioembolization cycles 1 and 2 without experiencing a DLT. DLT window will be 56 days (cycle 1, day 1 to cycle 2, day 28). Dose limiting toxicity will be reached when one of the clinical and/or laboratory parameters are met 56 days
Primary Maximum tolerated dose (MTD) Traditional 3+3 design will be used to determine the recommended dose for the dose expansion phase will be defined as the dose level just below this toxic dose level. Up to 4 years
Secondary Overall response rate (ORR) Radiographic overall response rate (measured in accordance to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) using imaging. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): 30% decrease in the sum of the longest diameter of target lesionsStable Disease (SD): Small changes that do not meet the criteria for CR, PR, or Progressive Disease (PD): 20% increase in the sum of the longest diameter of target lesions. ORR will be defined as a ratio of the number of patients who demonstrated complete response (CR) or partial response (PR) to the number of all evaluated patients. Up to 4 years
Secondary Progression-free survival (PFS) PFS will be defined as a time period that started at enrollment, during which a patient neither progressed nor died based on radiographic response. Up to 4 years
Secondary Hepatic progression-free survival (HPFS) HPFS will be defined as a time period that started at enrollment, during which a patient neither progressed in the liver nor died based on radiographic response. Up to 4 years
Secondary Extrahepatic progression free survival (EHPFS) EHPFS will be defined as a time period that started at enrollment, during which a patient neither progressed outside the liver nor died based on radiographic response Up to 4 years
Secondary Overall survival (OS) Overall Survival will be analyzed 12 months after the last patient is enrolled. Overall survival will be assessed using a two-sided, log-rank test. The survival function will be estimated using the Kaplan-Meier product limit method. In addition, two-sided 95% confidence intervals for the median overall survival will be computed Up to 12 months
Secondary Biomarker response Proportion of patients with carcinoembryonic antigen (CEA) response with = 50% decline from baseline (in patients with baseline level = 3.2) post combination therapy with Tas-102 and 90Y radioembolization. Maximum percent change will be calculated. CEA level will only be followed for participants with elevated level (=3.2) at baseline. Up to 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1